Horizon Technology Finance Supports BioVaxys in Strategic Acquisition of Immunotherapy Assets

### BioVaxys Technology Corp. Expands Immunotherapy Portfolio Through Strategic Acquisition

BioVaxys Technology Corp., a clinical-stage biopharmaceutical company based in Vancouver, BC, formalizes its acquisition of the assets and intellectual property from the former IMV Inc. This deal, documented in an Asset Purchase Agreement (APA) dated February 11, 2024, focuses on the DPX™ immune-educating platform technology. This platform is pivotal for BioVaxys as it develops novel immunotherapies aimed at treating a range of medical conditions, including various cancers and immunological diseases. The DPX™ technology is designed to instruct the immune system to generate customized immune responses, potentially revolutionizing treatment approaches in these critical areas.

The APA initially stipulates that BioVaxys must raise USD $10 million by December 31, 2024, to secure the acquisition fully. However, the company successfully negotiates amendments to extend this deadline to June 30, 2025, before further reducing the performance milestone to USD $2,028,636. On September 25, 2025, the milestone is adjusted down again to USD $1,785,625, showcasing a flexible approach to financing that allows BioVaxys to concentrate on its scientific developments without the immediate pressure of high fundraising targets. If the company meets this revised financial requirement by September 30, 2026, it can deactivate Section 12 of the APA, streamlining its operational focus and enhancing its strategic agility.

BioVaxys’s commitment to advancing its immunotherapy offerings is further highlighted by its clinical pipeline, notably the drug maveropepimut-S (MVP-S). Currently in Phase IIB development, MVP-S targets advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum-resistant Ovarian Cancer through the utilization of survivin-derived antigenic peptides. This strategic acquisition and ongoing clinical advancements reflect BioVaxys's dedication to improving patient care and its position in the rapidly evolving biopharmaceutical landscape.

In addition to the acquisition news, BioVaxys is actively pursuing collaborations that may bolster its research capabilities and extend its market reach. As the biopharmaceutical sector increasingly focuses on personalized medicine, companies like BioVaxys that innovate in immunotherapy are positioned for significant growth.

Looking ahead, the successful implementation of the DPX™ platform could provide BioVaxys with a competitive advantage in the biopharmaceutical industry, particularly as it addresses unmet medical needs in oncology and immunology. The company’s ability to refine and deliver effective therapies will be critical in establishing its reputation as a leader in the field.